Century Therapeutics SVP sells shares worth $273 to cover taxes

Published 05/02/2025, 23:38
Century Therapeutics SVP sells shares worth $273 to cover taxes

PHILADELPHIA—Carr Douglas, Senior Vice President of Finance & Operations at Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold 351 shares of the company’s common stock. The shares were sold at a price of $0.78 each, amounting to a total transaction value of $273. Following this sale, Douglas retains ownership of 316,796 shares in the company.

The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units. According to the filing, these sales were automatic and not at the discretion of Douglas. Want deeper insights into Century Therapeutics’ financial health and valuation? InvestingPro offers exclusive analysis and over 30 additional financial metrics not available to regular investors.

In other recent news, Century Therapeutics has reported significant developments in its operations. The company is set to launch a Phase 1/2 trial of its investigational cell therapy CNTY-101, in partnership with Friedrich-Alexander University Erlangen-Nürnberg. This trial, named CARAMEL, aims to evaluate the therapy’s potential in treating B-cell mediated autoimmune diseases.

Additionally, Century Therapeutics’ collaboration with Bristol-Myers Squibb (NYSE:BMY) has been terminated. The collaboration was initially aimed at researching and developing novel therapies for hematologic malignancies. Despite this change, Century Therapeutics plans to continue exploring opportunities related to acute myeloid leukemia and multiple myeloma.

In the realm of financial analysis, Piper Sandler has adjusted its price target for Century Therapeutics, maintaining an Overweight rating despite a significant reduction to $4 from the previous $12. On the other hand, Clear Street initiated coverage on Century Therapeutics with a Buy rating and a price target of $9.00, indicating a positive outlook on the company’s future performance.

These are the latest developments in the operations and financial analysis of Century Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.